Innovations Advanced by M&A

Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis

Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis

For many early-stage life sciences companies, mergers and acquisitions (M&A) represent a critical path. M&A helps companies unlock the complementary resources and expertise that help advance a new therapy from the lab to patients at scale. For example, Dermira’s acquisition by Eli Lilly & Co. helped bring Ebglyss, a novel monoclonal antibody treatment, to patients living with moderate-to-severe atopic dermatitis (AD).

read more
Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers

Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers

Life sciences companies of all sizes rely on mergers and acquisitions (M&A) to focus on what they do best, and then combine complementary resources and expertise to quickly and efficiently advance new treatments and cures to consumers. In the case of Ignyta’s acquisition by Roche, M&A played a pivotal role in accelerating a new precision therapy to patients battling rare forms of cancer.

read more
Innovations Advanced by M&A: New Treatment Options for Migraines

Innovations Advanced by M&A: New Treatment Options for Migraines

For many small and early-stage life science companies, making the leap from research and development (R&D) to manufacturing and distribution of a new treatment can be an insurmountable barrier. Pfizer’s acquisition of Biohaven Pharmaceuticals, for example, accelerated the global distribution of two new migraine therapies, while also allowing the early-stage company to continue pursuing new scientific breakthroughs.  

read more
Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers

Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers

By combining complementary resources and expertise among companies of all sizes – while driving investment across the ecosystem – M&A helps advance innovative new treatments and cures to patients. This was precisely the case for Retevmo and Jaypirica, two first-of-their-kind oncology treatments brought to market through the acquisition of Loxo Oncology by Eli Lilly & Co.

read more
Innovations Advanced by M&A: The First Therapy for Pompe Disease

Innovations Advanced by M&A: The First Therapy for Pompe Disease

From the complex scientific and regulatory expertise required, to the enormous capital investment needed for state-of-the-art facilities and clinical trials, many companies cannot navigate this path alone. Mergers and acquisitions (M&A) are fundamental to shepherding medicines along the path to market, and to patients in need. Such was the case for a first-of-its-kind treatment for Pompe disease.

read more